Álvarez-Torres BV, Godínez SA, Barrientos R, Rojas VF, Polanco M

Language: Spanish
References: 14
Page: 175-181
PDF size: 608.24 Kb.

ABSTRACT

Adrenocortical carcinoma is a rare heterogeneous tumor, incompletely understood especially pathogenically and poor prognosis. Patients usually present with symptoms of Cushing’s syndrome and mass effect. The tumors usually occur in both CT and MRI in homogeneous, irregular borders and differ from adenomas by their low fat content. Histopathology is the key to the diagnosis of malignancy and can also provide information regarding the diagnosis. In early stages (I to III) resection is the treatment of choise but local recurrences are frequent, particularly after capsular invasion. On patients not candidates for surgery, Op-DDD (1-chloro-2-[2,2-dichloride-1-(4-clorofenyl)- ethyl]-benzene) alone or in combination with other drugs patients remains the treatment of choice. In terms of distant spread, the cancer metastasizes lung 60%, liver 50%, nodes 48%, 24% bone, pleura and heart 1%. The case of a woman with adrenal carcinoma, Cushing syndrome, virilization and base of tongue metastasis and subcutaneous tissue is reported.

REFERENCES

1. Fassnacht M, Libé R, Kroiss M, Allolio B: Adrenocortical carcinoma: a clinician’s update. Nat Rev Endocrinol. 2011; 7: 323-35.

2. 2 Allolio B, Fassnacht M: Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab. 2006; 91: 2027-37.

3. Schteingart DE, Doherty GM, Gauger PG, Giordano TJ, Hammer GD, Korobkin M, Worden FP: Management of patient with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer. 2005; 12: 667-80.

4. World Health Organization Classification of Tumours. Pathology and genetics. Tumours of endocrine organs. Differential diagnosis. And molecular advances. IARC Press: Lyon.

5. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM: The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008; 93: 1526-40.

6. Espinosa de los Monteros-Sánchez AL, Valdivia-López J, Mendoza-Zubieta V, Mercado-Atri M, Gómez-Pérez F, Vergara-López A et al. Consenso en el diagnóstico y tratamiento del síndrome de Cushing. Revista de Endocrinología y Nutrición. 2007; 15: S3-S12.

7. Libè R, Fratticci A, Bertherat J: Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer. 2007; 14: 13-28.

8. Boscaro M, Arnaldi G: Approach to the patient with possible Cushing’s syndrome. J Clin Endocrinol Metab. 2009; 94: 3121-31.

9. Pivonello R, De Martino MC, De Leo M, Lombardi G, Colao A: Cushing’s Syndrome. Endocrinol Metab Clin North Am. 2008; 37: 135-49.

10. Lacroix A, Nieman LK, Martin KA. Clinical presentation and evaluation of adrenocortical tumors. 2011. UpToDate [Internet]. Available in: http://www.uptodate.com/contents/clinical-presentation-and-evaluation-of-adrenocortical-tumors

11. Morimoto R, Satoh F, Murakami O, Suzuki T, Abe T, Tanemoto M, Abe M, Uruno A, Isidoya S, Arai Y, Takahashi K, Sasano H, Itu S: Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr J. 2008; 55: 49-55.

12. Blanes A, Diaz-Cano SJ: Histologic criteria for adrenocortical proliferative lesions: value of mitotic figure variability. Am J Clin Pathol. 2007; 127: 398-408.

13. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A et al: Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012; 366: 2189-97.

14. Berruti A, Terzolo M, Sperone P, Pia A, Della Casa S, Gross DJ, Carnaghi C, Casali P, Porpiglia F, Mantero F, Reimondo G, Angeli A, Dogliotti L: Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer. 2005; 12: 657-66.